Compounds and methods for inhibiting nhe-mediated antiport in the treatment of disorders associated with fluid retention or salt overload and gastrointestinal tract disorders
AssigneeArdelyx, Inc.
InventorsNoah BELL, Christopher CARRERAS, Dominique CHARMOT, Jeffrey W. JACOBS, Michael Robert LEADBETTER, Marc NAVRE
Life of this patent
Estimating the term…
Abstract
The present disclosure is directed to compounds and methods for treating irritable bowel syndrome, chronic kidney disease and end stage renal disease by administering to a subject in need thereof a compound or a pharmaceutically acceptable salt thereof, wherein the compound has the structure
Claims15
A method of treating irritable bowel syndrome in a subject in need thereof comprising administering to the subject in need thereof an effective amount of a compound or a pharmaceutically acceptable salt thereof, wherein the compounds has the structure:
A method of treating chronic kidney disease in a subject in need thereof comprising administering to the subject in need thereof an effective amount of a compound or a pharmaceutically acceptable salt thereof, wherein the compounds has the structure:
A method of treating end stage renal disease in a subject in need thereof comprising administering to the subject in need thereof an effective amount of a compound or a pharmaceutically acceptable salt thereof, wherein the compounds has the structure:
Dependencies are inferred from the claim text.